# OnCo record nct05406401 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05406401/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05406401", "NCT05406401" ;
  schema:name "A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)"@en ;
  schema:alternateName "waveLINE-007"@en ;
  schema:description "A phase 2 trial of Zilovertamab vedotin, Cyclophosphamide, Doxorubicin, Rituximab and Prednisone in diffuse large B-cell lymphoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05406401/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05406401> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2022-07-14" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/zilovertamab-vedotin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/prednisone/> ;
  onco:companies <https://onco.cc/companies/merck/> .